Age: 12.0
Sex: M
Vaccine: FLU3, HEPA, IPV, MEN, MMR, TDAP
Symptoms: No adverse event, Product storage error
Clinical narrative: No additional AE; GARDASIL-9, RECOMBIVAXHB, and ROTATEQ had a prior excursion on 01-JUN-2023 as well as an excursion on 13-SEP-2023 and that these vaccines may have been administered to patients; This non-valid, spontaneous report was received from a Nurse and refers to an unspecified patient. The patient's medical history, concurrent conditions and concomitant therapies were not provided.  On an unknown date in 2023, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) injection (recombinant Human albumin), lot #W035197, expiration date: 24-MAY-2024, administered for prophylaxis (anatomical location, strength, and route of administration were not provided); rotavirus vaccine, live, oral, pentavalent (ROTATEQ) oral liquid, lot #1908330, expiration date: 18-NOV-2023, administered for prophylaxis (anatomical location, strength was not provided); hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, lot #1775827, expiration date: 27-JUN-2024, administered for prophylaxis (anatomical location, strength, and route of administration were not provided); and hepatitis b vaccine (recombinant) (RECOMBIVAX HB) intramuscular injection, lot #W002452 verified to be valid after internal review, expiration date: 26-FEB-2024, administered for prophylaxis (anatomical location, strength, and route of administration were not provided). Hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, hepatitis b vaccine (recombinant) (RECOMBIVAX HB) intramuscular injection, and rotavirus vaccine, live, oral, pentavalent (ROTATEQ) had prior excursions which took place on 01-JUN-2023 [above 47 F (59.1F) for 17 hours 16 minutes and 0 seconds] and 13-SEP-2023 (temperature: 51.6 F, time frame: 13 hours 0 minutes 0 seconds). Rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) injection had an excursion on 13-SEP-2023 (temperature 51.6F, time frame 13 hours 0 minutes 0 seconds) (product storage error). It was confirmed that no symptomatic effects or other adverse events were reported.  This is a non-valid report due to lack of the patient's identifiers.  Follow-up was received from a nurse on 26-JAN-2024: This spontaneous report  refers to a 13-year-old male. The patient's medical history included  developmental delay, and obstructive sleep apnoea syndrome. The patient's concurrent conditions included  down's syndrome, and prophylaxis. Concomitant therapies were not reported.  On 18-JAN-2023, the patient started therapy with diphtheria vaccine toxoid, pertussis vaccine acellular 5-component, tetanus vaccine toxoid (ADACEL), unk, administered intramuscularly for prophylaxis (strength, formulation, lot #, and expiry date were not provided). On 18-OCT-2023, the patient started therapy with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) subcutaneous injection, unk, lot #W035197, expiration date: 24-MAY-2024, administered subcutaneously for prophylaxis (strength was not provided); hepatitis a vaccine inact (HAVRIX), unk, administered intramuscularly for prophylaxis (strength, formulation, lot #, and expiry date were not provided); influenza vaccine inact split 3v (FLUARIX), unk, administered intramuscularly for prophylaxis (strength, formulation, lot #, and expiry date were not provided); polio vaccine inact 3v (vero) (IPOL POLIO VACCINE), unk, administered subcutaneously for prophylaxis (strength, formulation, lot #, and expiry date were not provided); and  meningococcal vaccine a/c/y/w conj (tet tox) (MENQUADFI), unk, administered intramuscularly for prophylaxis (strength, formulation, lot #, and expiry date were not provided).